|
N
|
n = 2510
|
n=1242
|
n = 1268
| |
|
Age, years
|
70.8 ± 8.1
|
71.4 ± 8.1
|
70.1 ± 8.0
|
< 0.001
|
|
BMI, kg/m2
|
26.2 ± 4.1
|
25.3 ± 3.6
|
27.0 ± 4.4
|
< 0.001
|
|
Current smoking, n (%)
|
551 (22.0)
|
547 (44.0)
|
4 (0.3)
|
< 0.001
|
|
Current alcohol drinking, n (%)
|
612 (24.4)
|
599 (48.2)
|
13 (1.0)
|
< 0.001
|
|
Baseline SBP, mmHg
|
153.3 ± 23.1
|
150.8 ± 22.3
|
155.7 ± 23.6
|
< 0.001
|
|
Baseline DBP, mmHg
|
85.3 ± 12.3
|
86.2 ± 12.5
|
84.3 ± 12.0
|
< 0.001
|
|
Self-reported hypertension, n (%)
|
1312 (52.3)
|
553 (44.5)
|
759 (59.9)
|
< 0.001
|
|
Self-reported diabetes, n (%)
|
424 (16.9)
|
161 (13.0)
|
263 (20.7)
|
< 0.001
|
|
Self-reported hyperlipidemia, n (%)
|
264 (10.5)
|
108 (8.7)
|
156 (12.3)
|
0.003
|
|
Self-reported atrial fibrillation, n (%)
|
46 (1.8)
|
26 (2.1)
|
20 (1.6)
|
0.335
|
|
Hypertension, n (%)b
|
2016 (80.3)
|
940 (75.7)
|
1076 (84.9)
|
< 0.001
|
|
Labor intensity, n (%)
| | | |
< 0.001
|
|
Mild
|
1885 (75.1)
|
887 (71.4)
|
998 (78.7)
| |
|
Moderate
|
488 (19.4)
|
280 (22.5)
|
208 (16.4)
| |
|
Severe
|
137 (5.5)
|
75 (6.0)
|
62 (4.9)
| |
|
Medication use, n (%)
|
|
Anti-platelet drugs
|
83 (3.3)
|
47 (3.8)
|
36 (2.8)
|
0.186
|
|
Lipid-lowering drugs
|
44 (1.8)
|
15 (1.2)
|
29 (2.3)
|
0.039
|
|
Glucose-lowering drugs
|
301 (12.0)
|
112 (9.0)
|
189 (14.9)
|
< 0.001
|
|
Anti-hypertensive drugs
|
1152 (45.9)
|
476 (38.3)
|
676 (53.3)
|
< 0.001
|
|
Laboratory results
|
|
TC, mmol/L
|
5.9 ± 1.2
|
5.6 ± 1.1
|
6.1 ± 1.3
|
< 0.001
|
|
TG, mmol/L
|
1.4 ± 0.9
|
1.2 ± 0.7
|
1.6 ± 0.9
|
< 0.001
|
|
HDL-C, mmol/L
|
1.6 ± 0.4
|
1.6 ± 0.4
|
1.6 ± 0.4
|
0.558
|
|
Glucose, mmol/L
|
6.3 ± 2.3
|
6.1 ± 2.1
|
6.4 ± 2.5
|
< 0.001
|
|
tHcy, μmol/L
|
13.9 ± 7.2
|
15.3 ± 8.6
|
12.5 ± 5.0
|
< 0.001
|
|
eGFR, mL/min/1.73 m2
|
92.5 ± 14.4
|
92.3 ± 15.1
|
92.7 ± 13.8
|
0.428
|
|
Vitamin E, μg/mL
|
14.0 ± 4.0
|
12.9 ± 3.3
|
15.2 ± 4.3
|
< 0.001
|
|
Selenium, ng/mL
|
87.2 ± 18.6
|
87.7 ± 18.6
|
86.8 ± 18.6
|
0.230
|
